InvestorsHub Logo
Followers 144
Posts 8676
Boards Moderated 0
Alias Born 10/07/2013

Re: Invest83838 post# 60346

Friday, 10/02/2015 7:40:25 AM

Friday, October 02, 2015 7:40:25 AM

Post# of 426376
I-

significant debt payments

Amarin current debt payment is 10% of Net Revenue (Pharmakon) and 3.5% interest on $150M till January 2017. $31,266k will be payable in January 2017 IF the Holders will request.

If scripts don't grow fast enough Amarin will dilute shares once again.

The current cash in hand (w/o add. milestone from Eddingpharm and w/o new ex-US deal) is more than enough till interim readout, so I do not expect any dilution before that. Nobody expect a significant (%) increase before Q4 (expect over-optimistics): we will see. Top of it Q1 will be interesting as coverage: we are approaching (in) the period when HCP prepare the next year formularies.

To reach bottom line break-even, the script# should be 45k, BUT if R-IT will be stopped @ interim 32k will be enough for it. As the stop could be happen in Q2 2016 as the earliest it is (w 1A communication, increased coverage) possible.

- - - - -
z- I do not know, I am an accountant only and speak Hunglish ... but settlement discussion is ongoing ...

Best,
G

#STRONGERTOGETHER

Disclosure: I am long with this stock. I wrote this post myself, and it expresses my own opinions (IMHO). I am not receiving compensation for it.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News